Analysts predict that Haemonetics Corporation (NYSE:HAE) will report sales of $226.86 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Haemonetics’ earnings, with the lowest sales estimate coming in at $224.80 million and the highest estimate coming in at $228.00 million. Haemonetics reported sales of $227.84 million in the same quarter last year, which indicates a negative year over year growth rate of 0.4%. The company is expected to announce its next quarterly earnings report before the market opens on Tuesday, February 6th.

On average, analysts expect that Haemonetics will report full-year sales of $226.86 million for the current year, with estimates ranging from $887.29 million to $901.63 million. For the next financial year, analysts expect that the firm will report sales of $931.76 million per share, with estimates ranging from $914.87 million to $960.01 million. Zacks’ sales calculations are an average based on a survey of analysts that cover Haemonetics.

Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.07. The company had revenue of $225.40 million during the quarter, compared to the consensus estimate of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. Haemonetics’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.38 EPS.

Several brokerages recently weighed in on HAE. Zacks Investment Research downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, November 20th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $43.00 target price (up previously from $38.00) on shares of Haemonetics in a report on Friday, October 6th. Jefferies Group upped their target price on shares of Haemonetics from $18.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, January 8th. Raymond James Financial raised shares of Haemonetics from an “underperform” rating to a “market perform” rating in a report on Tuesday, January 2nd. Finally, Craig Hallum reaffirmed a “hold” rating and issued a $50.00 target price (up previously from $40.00) on shares of Haemonetics in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. Haemonetics presently has an average rating of “Hold” and a consensus price target of $58.83.

Shares of Haemonetics (NYSE:HAE) traded down $0.18 during trading on Wednesday, reaching $63.94. 358,300 shares of the company traded hands, compared to its average volume of 537,520. The company has a market cap of $3,386.71, a P/E ratio of 799.35, a P/E/G ratio of 4.84 and a beta of 0.99. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51. Haemonetics has a one year low of $36.44 and a one year high of $64.99.

In other Haemonetics news, CAO Dan Goldstein sold 4,691 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $54.93, for a total value of $257,676.63. Following the sale, the chief accounting officer now owns 3,747 shares in the company, valued at approximately $205,822.71. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Willaim P. Burke sold 13,193 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $54.04, for a total transaction of $712,949.72. Following the completion of the sale, the chief financial officer now owns 27,227 shares in the company, valued at approximately $1,471,347.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,486 shares of company stock worth $3,050,827. Corporate insiders own 1.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in HAE. Riverhead Capital Management LLC raised its position in shares of Haemonetics by 79.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 1,507 shares in the last quarter. Shelton Capital Management purchased a new stake in shares of Haemonetics during the 2nd quarter valued at about $204,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Haemonetics during the 2nd quarter valued at about $260,000. Amalgamated Bank raised its position in shares of Haemonetics by 5.7% during the 2nd quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 392 shares in the last quarter. Finally, First Allied Advisory Services Inc. purchased a new stake in shares of Haemonetics during the 2nd quarter valued at about $316,000.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $226.86 Million” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/17/zacks-brokerages-expect-haemonetics-corporation-hae-will-announce-quarterly-sales-of-226-86-million.html.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Get a free copy of the Zacks research report on Haemonetics (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.